Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danial E Baker

Showing results (31-40 of 171) with videos related to

Pageof 18
Sort By:
Hospital Pharmacy|March 14, 2014
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Hospital Pharmacy|April 10, 2014
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Reviews in Gastroenterological Disorders|May 15, 2008
Pylera plus omeprazole: quadruple treatment for Helicobacter pyloriDanial E Baker
Hospital Pharmacy|June 25, 2014
Current FDA-Related Drug Information: Approvals, Submission, and Important LabelingChanges for US Marketed PharmaceuticalsDanial E Baker
Hospital Pharmacy|February 13, 2015
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Hospital Pharmacy|February 27, 2015
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Hospital Pharmacy|January 15, 2014
Breakthrough Drug Approval Process and Postmarketing ADR ReportingDanial E Baker
Hospital Pharmacy|April 1, 2024
DaprodustatDanial E Baker
Reviews in Gastroenterological Disorders|March 30, 2007
Natalizumab: overview of its pharmacology and safetyDanial E Baker
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 26, 2005
Rationale for using serotonergic agents to treat irritable bowel syndromeDanial E Baker
Pageof 18

Showing results (31-40 of 171) with videos related to

Sort By:
Pageof 18
Hospital Pharmacy|March 14, 2014
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Hospital Pharmacy|April 10, 2014
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Reviews in Gastroenterological Disorders|May 15, 2008
Pylera plus omeprazole: quadruple treatment for Helicobacter pyloriDanial E Baker
Hospital Pharmacy|June 25, 2014
Current FDA-Related Drug Information: Approvals, Submission, and Important LabelingChanges for US Marketed PharmaceuticalsDanial E Baker
Hospital Pharmacy|February 13, 2015
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Hospital Pharmacy|February 27, 2015
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Hospital Pharmacy|January 15, 2014
Breakthrough Drug Approval Process and Postmarketing ADR ReportingDanial E Baker
Hospital Pharmacy|April 1, 2024
DaprodustatDanial E Baker
Reviews in Gastroenterological Disorders|March 30, 2007
Natalizumab: overview of its pharmacology and safetyDanial E Baker
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 26, 2005
Rationale for using serotonergic agents to treat irritable bowel syndromeDanial E Baker
Pageof 18